EP1692176A4 - Anti-igf-i receptor antibody - Google Patents

Anti-igf-i receptor antibody

Info

Publication number
EP1692176A4
EP1692176A4 EP04811082A EP04811082A EP1692176A4 EP 1692176 A4 EP1692176 A4 EP 1692176A4 EP 04811082 A EP04811082 A EP 04811082A EP 04811082 A EP04811082 A EP 04811082A EP 1692176 A4 EP1692176 A4 EP 1692176A4
Authority
EP
European Patent Office
Prior art keywords
igf
receptor antibody
antibody
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04811082A
Other languages
German (de)
French (fr)
Other versions
EP1692176A1 (en
Inventor
Rajeeva Singh
Daniel J Tavares
Nancy E Dagdigian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunogen Inc
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of EP1692176A1 publication Critical patent/EP1692176A1/en
Publication of EP1692176A4 publication Critical patent/EP1692176A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP04811082A 2003-12-08 2004-12-07 Anti-igf-i receptor antibody Ceased EP1692176A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody
PCT/US2004/038230 WO2005061541A1 (en) 2002-06-14 2004-12-07 Anti-igf-i receptor antibody

Publications (2)

Publication Number Publication Date
EP1692176A1 EP1692176A1 (en) 2006-08-23
EP1692176A4 true EP1692176A4 (en) 2008-11-12

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04811082A Ceased EP1692176A4 (en) 2003-12-08 2004-12-07 Anti-igf-i receptor antibody

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX361668B (en) 2009-12-21 2018-12-11 Genentech Inc Antibody formulation.
AU2011253101A1 (en) * 2010-05-11 2013-01-10 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
EP2766478A4 (en) 2011-10-10 2015-06-17 Los Angeles Childrens Hospital Novel asparaginase and methods for treating diseases associated with asparagine dependence
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
WO2018221521A1 (en) * 2017-05-30 2018-12-06 帝人ファーマ株式会社 Anti-igf-i receptor antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody
WO2004071529A2 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
WO2003106621A2 (en) * 2002-06-14 2003-12-24 Immunogen, Inc. Anti-igf-i receptor antibody
WO2004071529A2 (en) * 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC; US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
See also references of WO2005061541A1 *
SURMACZ E: "Growth factor receptors as therapeutic targets: Strategies to inhibit the insulin-like growth factor I receptor", ONCOGENE, NATURE PUBLISHING GROUP, GB BASINGSTOKE, HANTS, vol. 22, no. 42, 29 September 2003 (2003-09-29), pages 6589 - 6597, XP002392351, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
MXPA06005540A (en) 2006-08-17
AU2004303792A1 (en) 2005-07-07
CA2548065A1 (en) 2005-07-07
JP2008502589A (en) 2008-01-31
BRPI0417406A (en) 2007-04-03
IL174770A0 (en) 2006-08-20
EA200600931A1 (en) 2006-10-27
EA009807B1 (en) 2008-04-28
NO20063155L (en) 2006-08-11
CR8426A (en) 2007-12-04
CN1886424A (en) 2006-12-27
EP1692176A1 (en) 2006-08-23
KR20070001883A (en) 2007-01-04
ECSP066595A (en) 2006-10-17

Similar Documents

Publication Publication Date Title
IL175710A0 (en) Anti-mpl antibody
IL175608A0 (en) Antibodies
PT1599504E (en) Modified antibody
EP1494693A4 (en) Cripto-specific antibodies
IL181575A0 (en) Anti-ox40l antibodies
IL228033A0 (en) Antibodies
PL375405A1 (en) Antibodies
IL172822A0 (en) Muscarnic acetylcholine receptor antagonists
AU2003257032A8 (en) Antibodies against c3a receptor
ZA200701952B (en) Anti-OX40L antibodies
IL173337A0 (en) Receptor
IL163580A0 (en) Assay for anti-ingap antibodies
EP1692176A4 (en) Anti-igf-i receptor antibody
EP1696949A4 (en) Vegf receptor antagonists
EP1780221A4 (en) Anti-synoviolin antibody
GB0306618D0 (en) Antibody
GB0414798D0 (en) Receptor
GB0306428D0 (en) Receptor proteins
GB0215389D0 (en) Receptor
GB0226878D0 (en) Antibodies
GB0321998D0 (en) Receptor
GB0418415D0 (en) Antibody
HK1209139A1 (en) Modified antibody
GB0329104D0 (en) Receptor
GB0307100D0 (en) Receptor

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060612

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: BA HR LV MK YU

RAX Requested extension states of the european patent have changed

Extension state: YU

Payment date: 20060612

Extension state: MK

Payment date: 20060612

Extension state: LV

Payment date: 20060612

Extension state: HR

Payment date: 20060612

Extension state: BA

Payment date: 20060612

Extension state: AL

Payment date: 20060612

A4 Supplementary search report drawn up and despatched

Effective date: 20081010

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101ALI20081006BHEP

Ipc: C07K 16/28 20060101ALI20081006BHEP

Ipc: C12N 15/00 20060101ALI20081006BHEP

Ipc: C07H 21/04 20060101ALI20081006BHEP

Ipc: C07K 16/00 20060101AFI20050708BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNOGEN, INC.

17Q First examination report despatched

Effective date: 20100211

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120719